Daré Bioscience Stock Is Trading Higher As Bacterial Vaginosis Candidate Secures FDA Priority Review

by Vandana Singh, Benzinga Editor

August 9, 2021 11:21 AM | 1 min read |

The FDA has accepted for review Daré Bioscience Inc's DARE marketing application for DARE-BV1 for bacterial vaginosis.
Under the priority review, the target goal date is December 7.
DARE-BV1 is an investigational thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% designed as a one-time treatment.
The application is supported by positive data from the DARE-BVFREE Phase 3 study, demonstrating 70-81% clinical cure rates from a single vaginal dose of DARE-BV1.
Price Action: DARE shares are up 7.45% at $1.73 during the market session on the last check Monday.
Related content: Benzinga's Full FDA Calendar.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.